Navigation Links
TorkLaw Responds to FDA Warning Letter to St. Jude Medical Regarding Defective Heart Device; Now Representing Patients in 15 States
Date:2/8/2013

LOS ANGELES, Feb. 9, 2013 /PRNewswire/ -- Product liability law firm TorkLaw continues to pursue litigation against St. Jude Medical on behalf of injured patients and their families.

In December 2011, the Food and Drug Administration issued a Class 1 recall for the St. Jude Medical Riata leads after many adverse events were being reported in patients. Studies showed that the leads which connect the heart defibrillator to the heart were failing due to insulation problems referred to as externalization.  A Class 1 Recall is the highest level recall that exists because the product poses a reasonable probability of serious adverse health consequences or death.

TorkLaw is now representing patients in fifteen states who have been affected by the recalled Riata leads and continues its ongoing investigation.  "We are speaking with patients from all over the country who have suffered from life-threatening injuries as a result of the defects found in St. Jude Medicals's heart devices," said Reza Torkzadeh , Senior Partner at TorkLaw.

The wires in the St. Jude Riata leads were found to protrude or perforate through the insulation resulting in lead failure, errant shocks, migration and other injuries.  Removal of leads is a very complex and potentially dangerous operation.   

"We are seeing a wide range of injuries caused by the defective leads.  All of these individuals have suffered a level of anxiety and pain that most of us will never understand," said Torkzadeh, who says his firm is committed to seeing that St. Jude is held accountable. 

The latest FDA investigation into St. Jude Medical was '/>"/>

SOURCE The Torkzadeh Law Firm
Copyright©2012 PR Newswire.
All rights reserved

Page: 1 2

Related medicine technology :

1. TorkLaw Accepting DePuy Hip Implant Cases
2. TorkLaw Accepting St. Jude Medical Device Cases
3. Medbox Responds to Unprecedented Rise in Stock Price
4. Omeros Responds to Misleading Announcement by Davis Wright Tremaine Concerning Settlement with Former Chief Financial Officer
5. Concord Medical Responds to Unusual Market Activity in its Stock
6. iMD Companies responds to shareholder questions
7. Icahn Responds To Forest Labs Board
8. Physician-Patient Alliance for Health & Safety: Addressing The Joint Commission Opioid Warnings Can Reduce Respiratory Depression and Improve Patient Safety in Hospitals
9. First Warning Systems Receives Investment by Members of the Reno Angels and Local Investors
10. National Sleep Expert Issues Warning about Popping Pills to Replace Sleep
11. Lifeline Biotechnologies First Warning Systems
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/15/2014)... Jan. 15, 2014 MultiCell Technologies, Inc. (OTC Bulletin ... provisional patent application concerning composition of matter, biological targets, ... tumor cell death.  This patent application ... stranded RNA molecules (VSRNAs) which interfere with the basic ...
(Date:1/15/2014)... , Jan. 15, 2014  According to Millennium Research ... market intelligence, the United States ... device markets will expand moderately through 2022, with ... In particular, increasing interest in drug-eluting beads (DEBs) ...
(Date:1/15/2014)... LAVAL, Quebec , Jan. 15, 2014  Valeant Pharmaceuticals ... VRX) announced that the applicable waiting period under the ... to the previously announced tender offer by its indirect ... the outstanding shares of common stock of Solta Medical, ...
Breaking Medicine Technology:MultiCell Technologies Files Patent Application Covering New Class of RNA Therapeutics 2MultiCell Technologies Files Patent Application Covering New Class of RNA Therapeutics 3US and European Transcatheter Embolization and Occlusion Device Market to Surpass $1.6 Billion by 2022 2US and European Transcatheter Embolization and Occlusion Device Market to Surpass $1.6 Billion by 2022 3Valeant Pharmaceuticals Announces Receipt Of Antitrust Clearance For Its Previously Announced Acquisition Of Solta Medical, Inc. 2Valeant Pharmaceuticals Announces Receipt Of Antitrust Clearance For Its Previously Announced Acquisition Of Solta Medical, Inc. 3
... Presented Along With Updated Phase 1 Colorectal Cancer ... Data at ... CHICAGO, June 1 /PRNewswire-FirstCall/,-- Poniard Pharmaceuticals, Inc. (Nasdaq: PARD ... results,from its ongoing randomized Phase 2 clinical trial in patients ...
... Greater Than 50% Response Rate and 100% Disease Control Rate Observed ... Patients with Medullary Thyroid Cancer, ... encouraging new data from an ongoing phase 1 clinical trial of,XL184, ... with advanced malignancies. The maximum tolerated dose (MTD) for,XL184 has been ...
Cached Medicine Technology:Poniard Announces Positive Preliminary Efficacy and Safety Data From Ongoing Phase 2 Trial of Picoplatin in First-Line Treatment of Colorectal Cancer 2Poniard Announces Positive Preliminary Efficacy and Safety Data From Ongoing Phase 2 Trial of Picoplatin in First-Line Treatment of Colorectal Cancer 3Poniard Announces Positive Preliminary Efficacy and Safety Data From Ongoing Phase 2 Trial of Picoplatin in First-Line Treatment of Colorectal Cancer 4Poniard Announces Positive Preliminary Efficacy and Safety Data From Ongoing Phase 2 Trial of Picoplatin in First-Line Treatment of Colorectal Cancer 5Exelixis Reports Encouraging Phase 1 Data for XL184 at ASCO 2Exelixis Reports Encouraging Phase 1 Data for XL184 at ASCO 3Exelixis Reports Encouraging Phase 1 Data for XL184 at ASCO 4Exelixis Reports Encouraging Phase 1 Data for XL184 at ASCO 5Exelixis Reports Encouraging Phase 1 Data for XL184 at ASCO 6
(Date:4/17/2014)... MD, was recently invited to submit a review ... Microbiology , one of the world,s foremost scientific ... specialist, and chair of the Department of Pediatrics ... analyzed the epidemiology and microbiology of co-infections during ... as more recent 2009 novel H1N1 pandemic. ...
(Date:4/17/2014)... 17, 2014) Doctors who treat patients with ... (LAM) can face an agonizing treatment decision. , ... disease and help relieve shortness of breath. But ... sirolimus can cause potentially fatal complications following transplantation. ... Daniel Dilling, medical director of Loyola University Medical ...
(Date:4/17/2014)... Colic affects about one in five infants in the ... during the first several months after birth. Research into ... promise; however, the April 1, 2014 issue of the ... on a study, "Probiotics and Infant Colic," concluding that ... for infant colic did not reduce crying or ...
(Date:4/17/2014)... 17, 2014 EcoHealth Alliance, a nonprofit organization that ... a comprehensive review today examining the current state of ... review calls for improved global surveillance strategies to combat ... outbreak of Ebola in West Africa that has claimed ... Guinea and Liberia. According to the World Health ...
(Date:4/17/2014)... A. Arias, M.D., Ph.D., at The University of Texas ... new superbug that caused a bloodstream infection in a ... issue of The New England Journal of Medicine ... class of highly-resistant bacteria known as methicillin-resistant Staphylococcus ... of hospital and community-associated infections. The superbug has also ...
Breaking Medicine News(10 mins):Health News:Patients with rare lung disease face agonizing treatment dilemma 2Health News:Patients with rare lung disease face agonizing treatment dilemma 3Health News:New study says probiotic use for infant colic is not effective in reducing symptoms 2Health News:Re-emergence of Ebola focuses need for global surveillance strategies 2Health News:Re-emergence of Ebola focuses need for global surveillance strategies 3Health News:New MRSA superbug emerges in Brazil 2
... Prevention Toolkit, a collection of resources designed to ... interacting with HIV-positive patients. The goal is ... risk and decrease the spread of HIV. ... AIDS Prevention Studies, includes proven prevention interventions for ...
... performing a hysterectomy is common practice to prevent the ... performed in 55 percent of all US women having ... article in the March/April issue of t Philadelphia, PA, ... oophorectomy) while performing a hysterectomy is common practice to ...
... with key beliefs and male monogamy , TUESDAY, March ... atheists tend to have higher IQs than those who are ... IQs also seem to make men less likely to cheat. ... fidelity than men with lower IQs, although the same association ...
... drugs in the pipeline, review finds , TUESDAY, March ... studies published in major medical journals answer the fundamental ... works best for a particular condition. , So concludes ... where experts seek to determine which available medicine is ...
... disease, CDC says, upping risks for transmitting it to others, ... one in six Americans is infected with herpes simplex virus ... of the most common sexually transmitted diseases (STDs) in the ... lifetime, causing recurrent and painful genital sores, according to the ...
... ... , , ... 9, 2010 -- More than 15.7 million women are HIV positive world-wide. In fact one ... States is diagnosed with HIV . These statistics underline the critical need for women and ...
Cached Medicine News:Health News:New study questions benefits of elective removal of ovaries during hysterectomy 2Health News:Do Liberals, Atheists Have Higher IQs? 2Health News:Do Liberals, Atheists Have Higher IQs? 3Health News:Most Drug Studies Don't Help Docs Pick Best Treatment 2Health News:Most Drug Studies Don't Help Docs Pick Best Treatment 3Health News:Herpes Infects One in Six in U.S. 2Health News:Herpes Infects One in Six in U.S. 3Health News:Herpes Infects One in Six in U.S. 4Health News:Herpes Infects One in Six in U.S. 5Health News:March 10 is National Women and Girls with HIV/AIDS Awareness Day 2Health News:March 10 is National Women and Girls with HIV/AIDS Awareness Day 3
Protects the eye during or after surgery or trauma. 8mm diameter, lint free keeps cornea moist. Protects retina from operating microscope light rays....
... designed specifically for posteror segment surgical procedures. ... fluid. A high pressure luer lock tubing ... 8in (20cm) long. ID - .02in (.50mm); ... with standing injections of viscoelastic fluids. 30G ...
... specifically for posteror segment surgical procedures. For ... A high pressure luer lock tubing set ... (20cm) long. ID - .02in (.50mm); OD ... standing injections of viscoelastic fluids. 30G (.30mm) ...
... Product designed specifically ... procedures.Designed for injection of ... viscous fluids. Special high ... to thinwall cannula. May ...
Medicine Products: